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A B S T R A C T
Macrolides and lincosamides are important antibacterials for the treatment of many common infections
in cattle and pigs. Products for in-feed medication with these compounds in combination with other
antimicrobials are commonly used in Europe. Most recently approved injectable macrolides have very
long elimination half-lives in both pigs and cattle, which allows once-only dosing regimens. Both in-feed
medication and use of long-acting injections result in low concentrations of the active substance for
prolonged periods, which causes concerns related to development of antimicrobial resistance.
Acquired resistance to macrolides and lincosamides among food animal pathogens, including some
zoonotic bacteria, has now emerged. A comparison of studies on the prevalence of resistance is diﬃcult,
since for manymicro-organisms no agreed standards for susceptibility testing are available. With animal
pathogens, the most dramatic increase in resistance has been seen in the genus Brachyspira. Resistance
towards macrolides and lincosamides has also been detected in staphylococci isolated from pigs and
streptococci from cattle. This article reviews the use of macrolides and lincosamides in cattle and pigs, as
well as the development of resistance in target and some zoonotic pathogens. The focus of the review is
on European conditions.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Introduction
Macrolides are classiﬁed according to the number of atoms
which comprise the lactone ring, ranging from 12 to 16 members
(Yao and Moellering, 2007) (Table 1). The ﬁrst macrolide intended
for food animal use was spiramycin, which was introduced in the
early 1960s, followed by erythromycin and tylosin in the early
1970s (Prescott, 2008). The most recent macrolide to be approved
in the EU was tildipirosin in 2011. Semi-synthetic, new generation
macrolides, the azalides, were introduced into human medicine in
the early 1990s (Ballow and Amsden, 1992; Bryskier and Butzler,
2003). The ﬁrst azalide for animal use, gamithromycin, was
approved for use within the European Union (EU) in 2008.
Lincomycin and its semi-synthetic derivatives clindamycin and
pirlimycin, belong to the lincosamides. In addition, streptogramins
(A and B) are classiﬁed along with macrolides and lincosamides
(Edelstein, 2004). The only streptogramin used for animals is
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virginiamycin, which, until 1998, was approved in the EU as a feed
additive for production enhancement of food animals; it is still
approved for this use in the US.
Macrolide antimicrobials inhibit bacterial protein synthesis via
binding to the 50S subunit of the ribosome. They bind preferen-
tially to the 23S rRNA of the 50S subunit, which overlaps with the
binding site of lincosamides and streptogramin B, but differs from
those of phenicols like chloramphenicol, and pleuromutilins. Due
to this similar mechanism of action, resistance is also often linked,
and macrolides, lincosamides and streptogramins B are often
referred to as the MLSB group. Macrolide and lincosamide (ML)
antibacterials have generally a bacteriostatic action, which is
mainly time-dependent (Giguère 2013a, 2013b). Some new gener-
ation macrolides can have bactericidal activity against some bac-
terial species, in laboratory conditions, although this effect is
limited compared with other classes of antimicrobials (Seral et al.,
2003).
ML antimicrobials are active against many Gram-positive bac-
terial genera such as Streptococcus, Staphylococcus, Enterococcus
and Trueperella (Arcanobacterium), as well as against Gram-
negative organisms, like Actinobacillus, Haemophilus, Histophilus,
Mannheimia, Pasteurella, Moraxella, Bordetella, Campylobacter and
Lawsonia. Anaerobes including Fusobacterium, Clostridium and
Bacteroides spp. are usually susceptible. In addition, the spectrum
covers spirochaetes (Leptospira, Brachyspira), and Mycoplasma.
However, substantial differences exist between macrolides in
their activity against different organisms (Hardy et al., 1988;
Bryskier and Butzler, 2003). The spectrum of activity of
lincosamides is similar but not identical than that of macrolides;
for example, Enterococcus faecalis is intrinsically resistant to
lincosamides (Roberts, 2008). Lincosamides have low activity
against Pasteurellaceae (Giguère 2013b).
In vitro susceptibility testing for ML antimicrobials is problem-
atic for many bacterial species, since guidelines for determination
of minimal inhibitory concentrations (MIC) do not include all
micro-organisms (Schwarz et al., 2010; CLSI, 2013). Comparison of
resistance data is also diﬃcult because different antimicrobials are
often tested and criteria for interpretation may differ.
Macrolides penetrate well into tissues (Giguère 2013a; Rose
et al., 2013). ML build up high intracellular concentrations and
accumulate within phagocytes (Scorneaux and Shryock, 1999). The
actual eﬃcacy of bacterial killing within cells has not been unam-
biguously demonstrated (Madgwick et al., 1989; Barcia-Macay
et al., 2006). After oral administration, macrolides are absorbed
incompletely. Lincosamides are absorbedwell when given orally to
monogastric animals. ML antibiotics are eliminated mainly by the
liver, with a variable part of the drug excreted in bile as the parent
drug or metabolites. This leads to enterohepatic cycling and long
terminal half-lives.
Semi-synthetic macrolides are very long-acting, due to their
low clearance rates. For example, the elimination half-life of
tulathromycin in cattle and swine is close to 4 days and that of
gamithromycin in cattle is >2 days. The most recently authorised
macrolide, tildipirosin, has the longest terminal half-life, approxi-
mately 9 days in cattle and >4 days in swine. Quantiﬁable concen-
trations of gamithromycin and tildipirosin are present for >2weeks
in plasma and 3–4 weeks in the lung (Giguère et al., 2011; Menge
et al., 2012). Severe tissue irritation, causing pain and inﬂamma-
tion, is a common problem of all macrolides, particularly when
administered parenterally (Giguère 2013a).
Use of ML antimicrobials in cattle and pigs
By 2013, eight macrolides and two lincosamides were autho-
rised for use in food animals in some or all EU member states
(Table 1). In the EU, ML are available for parenteral administration,
including intramammary use, and for oral use including premix
formulations. ML are used widely for the treatment of common
infections in food-producing animals, and have been categorised
as critically important in veterinary medicine by the World
Organisation for Animal Health (OIE) (Collignon et al., 2009).
Use of macrolides as growth promoters began at the same time
as therapeutic use, with spiramycin and tylosin being used within
the EU until 1998 (Council Regulation EC2821/98 of 17 December
1998). The ﬁrst injectable, long-acting macrolide with a one-dose
only regimen for food animal use was tilmicosin. Other macrolides
authorised with this regimen are tulathromycin, gamithromycin
and tildipirosin. The total number of available ML products varies
between EU member states from 5 to 183 products contain-
ing macrolides (Fig. 1) and from 1 to 32 products containing
lincosamides. More than 60 combination products containing
macrolides and other antimicrobials are available in the EU; in
addition, numerous lincomycin products exist as combinations
(EMA/CVMP/SAGAM, 2011). Most often macrolides are combined
with colistin or aminoglycosides, but in some products also with
sulfonamides, trimethoprim, oxytetracycline, or ampicillin. The
approved duration of treatment for some in-feed products is long,
up to 4–5 weeks in some cases.
In a recent report (EMA/ESVAC, 2013), data on the sales of anti-
bacterials in 25 European countries were analysed in a harmonised
manner using population correction unit (PCU) as an estimate of
the eligible animal population. In Fig. 2, data on the sales of ML in
different European countries in 2011 are presented. Usage of ML
varies greatly between countries, as does proportion of total anti-
microbial sales which are ML (ranging from 4% in Sweden to 14% in
Denmark), with pigs being the main target species for ML use. The
use of different pharmaceutical forms of ML also differs widely
between countries (EMA/ESVAC, 2013). For macrolides, sales
Table 1
Macrolides and related compounds and their approval for animal use in the EU (EMA/CVMP/SAGAM, 2011).
Macrolides Lincosamides Streptogramins (A,B)
14-Membered ring 15-Membered ring 16-Membered ring
Clarithromycin Azithromycin Josamycin Clindamycinb Pristinamycin
Erythromycina Gamithromycina Mideacamycin Lincomycina Quinupristin/dalfopristin
Oleandomycin Tulathromycina Miocamycin Pirlimycina Virginiamycinc
Roxithromycin Rokitamycin
Telithromycina Spiramycina
Tildipirosina
Tilmicosina
Tylosina
Tylvalosina
a Substances approved for veterinary use in one or more member states in the EU (having marketing authorisation [MA]).
b Only approved for small animal use.
c Not any longer approved in the EU.
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comprise premixes, oral powders, oral solutions and injectable
products (Fig. 3), while for lincosamides almost all of the sales
were products for in-feed medication (Fig. 4).
Older macrolide products have various indications and dose
regimens. The main indications in cattle include all common
infections such as respiratory and genital infections, foot lesions
and mastitis, and, in pigs, pneumonia, enteritis and arthritis are
label indications. More recently approved ML products list the
target pathogens, with injectable macrolides indicated for the
treatment and prevention of respiratory infections in non-
lactating cattle caused by Mannheimia haemolytica, Pasteurella
multocida, Histophilus somni, or Mycoplasma bovis. Tulathromycin
is also indicated for interdigital necrobacillosis associated with
Fusobacterium necrophorum and Porphyromonas levii, and for
treatment of infectious bovine keratoconjunctivitis associated
with Moraxella bovis. In swine, injectable macrolides are indicated
for the treatment and prevention of swine enzootic pneumonia
caused by Mycoplasma hyopneumoniae, and respiratory infections
caused by Actinobacillus pleuropneumoniae, P. multocida, and
Haemophilus parasuis (EMA, 2010). Tylvalosin is authorised cen-
trally in the EU for the oral treatment and prevention of porcine
proliferative enteropathy caused by Lawsonia intracellularis, swine
dysentery caused by Brachyspira hyodysenteriae, as well as swine
enzootic pneumonia.
Fig. 1. Number of macrolide products authorised for food animal use per antimicrobial substance in Europe (25 countries, data from 2011). Data collected in the European
Medicines Agency.
Fig. 2. Sales of macrolides and lincosamides in 25 European countries in 2011 expressed asmg of active ingredient per population correction unit (PCU) for all food-producing
species, including horses. Data from ESVAC (EMA/ESVAC, 2013).
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Fig. 3. Sales of macrolides in 24 European countries (no sales in Iceland or Norway) in 2011 by pharmaceutical form expressed as percentage of the sales in tonnes in each
country. No sales in Iceland. In addition, negligible amounts were sold as intramammary and/or intrauterine preparations in some countries. Data from ESVAC (EMA/ESVAC,
2013).
Fig. 4. Sales of lincosamides in 23 European countries in 2011 by pharmaceutical form expressed as percentage of the sales in tonnes in each country. No sales in Norway
or Sweden. Data from ESVAC (EMA/ESVAC, 2013).
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Resistance to ML antibiotics
Mechanisms of resistance
Macrolide-producing Streptomycetes are intrinsically ML-
resistant as they have genes which provide a self-protective mech-
anism (Andini and Nash, 2006). Enterobacteriaceae such as E. coli
and Salmonella spp. have a low susceptibility to macrolides,
because of the poor permeability of these hydrophobic substances
across their bacterial wall (Vaara, 1993). Gram-negative non-
fermentative rods like Pseudomonas aeruginosa and Acinetobacter
are inherently resistant to ML antimicrobials.1 More than 70 genes
encoding for acquired ML resistance are hosted by more than 60
different bacterial species (Roberts, 2011; van Hoek et al., 2011).
The most common resistance mechanism against ML antibiot-
ics is a target site modiﬁcation mediated by at least 36 different
rRNA methylases (erm genes) (Leclercq and Courvalin, 1991; Diner
and Hayes, 2009; Palmieri et al., 2013). These genes, the most
prevalent being erm(A), erm(B), and erm(C), have been detected in
numerous streptococci and staphylococci including Strep. suis,
Strep. uberis, Staph. hyicus, and Staph. aureus, as well as many other
food animal pathogens such as Enterococcus, M. haemolytica,
P. multocida, Trueperella pyogenes and Listeria monocytogenes
(Jensen et al., 1999; Boerlin et al., 2001; Martel et al., 2001, 2003;
Jost et al., 2003; Culebras et al., 2005; Loch et al., 2005; Luthje and
Schwarz, 2007; Luthje et al., 2007; Palmieri et al., 2007; Schmitt-
Van de Leemput and Zadoks, 2007; Desmolaize et al., 2011; Haenni
et al., 2011; Kadlec et al., 2011; Zastempowska and Lassa, 2012).
Erm genes can be transferred horizontally because of the associa-
tion with mobile genetic elements (Roberts, 2011).
A Cfr gene encoding for an unusual rRNAmethylase and confer-
ring a multi-drug resistance phenotype (including resistance to
lincosamides, streptogramins A, phenicols, pleuromutilins, and
oxazolidinones) has been detected in several bacterial species
including staphylococci, enterococci and E. coli from food animals
(Schwarz et al., 2002; Witte and Cuny, 2011; Liu et al., 2012; Zhang
et al., 2014). This gene is of global concern as it is often located on
plasmids and can be spread between bacterial species and genera
(Shen et al., 2013).
The second most common ML resistance mechanism is the
active expulsion of the antimicrobial from the bacteria mediated
by eﬄux pump genes (mef andmsr).Mef genes confer resistance to
ML antibiotics and msr genes to both ML and streptogramin B.
Many of the mef genes are associated with conjugative elements
located in the chromosome, whereasmsr genes are located mainly
on plasmids. Chromosomalmsr(E) was detected in P. multocida and
M. haemolytica strains isolated from bovine respiratory disease
(Kadlec et al., 2011). The mef(A) gene has been reported in strep-
tococci, including Strep. suis (Martel et al., 2003). Other eﬄux genes
are vga genes which have previously been detected in streptococ-
cal and enterococcal species and code for transferable resistance to
pleuromutilins, streptogramin A and lincosamides (De Graef et al.,
2007). Vga(C) and vga(E) were found in porcine methicillin-
resistant Staph. aureus (MRSA) isolates of type ST398 (Kadlec et al.,
2009, 2011; Kadlec and Schwarz, 2009; Schwendener and
Perreten, 2011) and vga(A) and vga(E) in bovine ST398 Staph.
aureus isolates (Fessler et al., 2010; Hauschild et al., 2012). One
more eﬄux gene lsa, which is intrinsic in E. faecalis and confers
resistance to lincosamides and streptogramin B, has recently been
detected in MRSA of swine origin (Li et al., 2013).
The third resistance mechanism is enzyme-catalysed inactiva-
tion of the drug mediated by phosphorylases (mph genes) confer-
ring resistance only to macrolides, or transferases that render the
bacteria resistant only to streptogramin A. Genes encoding for
inactivating enzymes have been detected in food animal patho-
gens, including mph(C) in Staph. aureus and lnu/lin in Staph. hyicus
and other coagulase-negative staphylococci (CNS) (Luthje and
Schwarz, 2007; Luthje et al., 2007; Sampimon et al., 2011). Strep.
uberis has been shown to expressmph(B) or lin(B) (Schmitt-Van de
Leemput and Zadoks, 2007; Achard et al., 2008; Haenni et al.,
2011). A bovine P. multocida strain has been reported to carry the
mph(E) gene in addition tomsr(E) in its chromosome (Kadlec et al.,
2011). Rare enzymes causing resistance are lyases (vgb genes)
which confer resistance to streptogramin B and esterases (ere
genes) conferring resistance to erythromycin (Morar et al., 2012).
Non-transferable resistance due to mutations in ribosomal
RNA and ribosomal proteins can also lead to reduced macrolide
susceptibility. Mutational events of the 23S rRNA confer MLS
resistance (Vester and Douthwaite, 2001) and are the most preva-
lent or the only known resistance mechanism in certain food
animal pathogens, including B. hyodysenteriae, B. pilosicoli, and
M. hyopneumoniae (Karlsson et al., 1999, 2004b; Stakenborg
et al., 2005; Hidalgo et al., 2011), as well as zoonotic organisms
Campylobacter jejuni and C. coli (Gibreel and Taylor, 2006;
Alfredson and Korolik, 2007; Caldwell et al., 2008).
Emergence of resistance to ML antibiotics in pathogens isolated
from cattle
Macrolide resistance of P. multocida isolated from cattle is rare
within the EU (Kehrenberg et al., 2006; Kaspar et al., 2007). In The
Netherlands, in 2004–2005 0% and in 2006–2008 2.5% of isolates
from cattle were reported to be resistant to tilmicosin, and no
resistance to tulathromycin was found (MARAN, 2007–2008). In
France in 2008, 7% of P. multocida but 35% of M. haemolytica iso-
lated from cattle were resistant to tilmicosin (AFSSA, 2009). In
Belgium, 13% of P. multocida isolates and 38% of M. haemolytica
isolates from healthy cattle, including veal calves, were reported to
be non-susceptible to tilmicosin (Catry et al., 2005). In The Neth-
erlands, resistance to tilmicosin forM. haemolyticawas reported to
increase from zero to 6.5% (MARAN, 2007–2008), and the same
ﬁgure was found for tulathromycin. Data from the US and Canada
suggest that MICs for bovine M. haemolytica and P. multocida
towards macrolides have increased. Portis et al. (2012) using the
same breakpoints as used in European studies reported that in
2009, 25% of M. haemolytica isolates and 24% of P. multocida were
not susceptible to tilmicosin; for tulathromycin the same ﬁgures
were 9% and 4%, respectively.
Data on H. somni from cattle are scarce, but Portis et al. (2012)
reported that the proportion of H. somni isolates from cattle which
were non-susceptible to tilmicosin and tulathromycin increased
from 3% and 2% in 2000 to 18% and 17% in 2009.
Macrolide resistance in Staph. aureus retrieved from bovine
mastitis has generally been uncommon: 0–2% of the isolates have
been reported to be resistant to erythromycin (Hendriksen et al.,
2008). Higher ﬁgures were seen in Estonia where 5% of Staph.
aureus mastitis isolates were resistant to erythromycin and as
much as 18% to clindamycin (Kalmus et al., 2011). Resistance of
Staph. aureus to clindamycin has not been recorded in the Nordic
countries (Pitkala et al., 2004; NORM-VET, 2005–2008). For
pirlimycin, 4% of the isolates were resistant in The Netherlands
(MARAN, 2007–2008). Coagulase-negative staphylococci (CNS)
have developed resistance to ML antimicrobials (Luthje and
Schwarz, 2006; Sampimon et al., 2011), with 13–20% of CNS iso-
lated from bovine mastitis in The Netherlands, Estonia and France
resistant to lincosamides (MARAN, 2007–2008; AFSSA, 2009) and
14–15% to erythromycin (Botrel et al., 2010). This is less marked in
the Nordic countries, where resistance to macrolides has been
4–6%, and no resistance to clindamycin has been found (Pitkala
et al., 2004; NORM-VET, 2005–2008).
In some European countries, up to 22% of Strep. uberis and 17%
of Strep. dysgalactiae isolates from bovinemastitis have been found
to be resistant to erythromycin (Hendriksen et al., 2008); in a
French study, 13–17% of Strep. uberis and 4–6% of Strep. dysgalactiae
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isolates from clinical and subclinical mastitis were resistant to
erythromycin, spiramycin and lincomycin (Botrel et al., 2010). Data
from The Netherlands revealed that 43% of Strep. uberis and 8% of
Strep. dysgalactiae were resistant to clindamycin (MARAN, 2007–
2008). In Sweden andNorway, no resistance towards erythromycin
or clindamycinwas reported for Strep. uberis and Strep. dysgalactiae
(NORM-VET, 2005–2008; SVARM, 2002–2010). In Finland, 15% of
Strep. uberis isolates were resistant to erythromycin but none to
clindamycin; Strep. dysgalactiae isolates were fully susceptible for
both (FINRES-Vet, 2005–2009).
In vitro susceptibility testing of Mycoplasma is challenging, due
to their slow growth and need for speciﬁcmedia, and consequently
little is known about ML resistance ofMycoplasma species isolated
in food animals (Aarestrup and Kempf, 2006). Acquired resistance
towards macrolides has been suspected in M. bovis isolated from
cattle in some countries (Thomas et al., 2003; Gerchman et al.,
2009).
Emergence of resistance to ML antibiotics in pathogens isolated
from pigs
For Brachyspira isolated from swine, high levels of ML resistance
have been reported for tylosin in most EU countries, with close to
100% of the isolates being resistant (FINRES-Vet, 1999; SVARM,
2002–2010; Vyt andHommez, 2006;MARAN, 2007–2008; Hidalgo
et al., 2009, 2011). Resistance to ML antimicrobials can develop
rapidly in B. hyodysenteriae because only a single transversion
mutation in one position of the 23S rRNA gene is required
(Karlsson et al., 1999; Pringle et al., 2012). Data on susceptibility of
Brachyspira to tylvalosin are limited, but isolates with high MIC
values to tylosin have generally also had higher MICs to tylvalosin
(Karlsson et al., 2004a; Hidalgo et al., 2011; Pringle et al., 2012).
Recently, tentative wild-type cut-off values have been proposed
for B. hyodysenteriae (Pringle et al., 2012). Resistance of
B. hyodysenteriae towards lincomycin is close to that for tylosin
(SVARM, 2002–2010; FINRES-Vet, 2005–2009), due to complete
cross-resistance.
In a US study, MIC values for Brachyspira species isolated from
pigs with clinical disease were reported to be consistently high
to lincomycin (Clothier et al., 2011). In Europe, resistance in
B. pilosicoli to tylosin has been reported to be 50–100%; also occa-
sional high MICs for tylvalosin have been reported (SVARM, 2002–
2010; Karlsson et al., 2004b; Pringle et al., 2006a; Pringle et al.,
2012). Isolates of B. hyodysenteriae have been found with simulta-
neous resistance to lincomycin, tylosin, tylvalosin and tiamulin
(Duinhof et al., 2008). For L. intracellularis, there are no standards
for susceptibility testing and practically no data are available. The
activity of tylosin and lincomycin was tested against 10 isolates of
L. intracellularis (Wattanaphansak et al., 2009). The wide range of
MIC distribution may indicate decreased susceptibility.
Results from in vitro susceptibility testing of Mycoplasma
should be interpreted with caution as no agreed standards for
testing are available. M. hyopneumoniae strains are intrinsically
resistant to 14-membered macrolides. Development of resistance
in M. hyopneumoniae towards 15- and 16-membered macrolides
and lincosamides has been reported in Belgium (Vicca et al.,
2004; Stakenborg et al., 2005). In a limited study from the US,
ﬁeld isolates of M. hyopneumoniae were reported to be fully sus-
ceptible to clindamycin and tylosin, but 25% were resistant to
tulathromycin (Schultz et al., 2012). Resistance of M. hyosynoviae
isolated from swine has been studied in Denmark; in 1968–1971
all isolates were susceptible to lincomycin and tylosin, but 20
years later 12% of isolates were resistant to tylosin (Aarestrup and
Friis, 1998).
For A. pleuropneumoniae isolated from swine, data are limited.
In France, close to 80% of A. pleuropneumoniae were resistant to
spiramycin, but only 2% to tilmicosin (AFSSA, 2009). In Spain, MIC
values of A. pleuropneumoniae for erythromycin increased com-
pared with those reported two decades earlier (Gutierrez-Martin
et al., 2006); however, trends such as these should be interpreted
with caution since laboratory methods may not be the same. Mac-
rolide resistance of P. multocida isolated from swine is rare within
the EU (Kehrenberg et al., 2006; Kaspar et al., 2007). In France in
2008, no resistance to tilmicosin was found in porcine isolates of
P. multocida, but 86% of the isolates were resistant to tylosin
(AFSSA, 2009).
Staph. hyicus isolated from swine is more frequently resistant to
macrolides (Werckenthin et al., 2001). The occurrence of macrolide
resistance of Staph. hyicus isolated from swine in Denmark appears
to correlate with the use of tylosin for growth promotion. The
proportion of Staph. hyicus isolates resistant to erythromycin
increased from 33% in 1996 to 62% in 1997, and decreased by
2001 to approximately 20%, thereafter stabilising at about 35%
(Aarestrup and Schwarz, 2006; DANMAP, 2012). Tylosin is still
used for treatment, which probably maintains the resistance at the
present level. In Sweden, 12% of Staph. hyicus were resistant to
erythromycin over a long time period (SVARM, 2002–2010).
Increasing resistance for macrolides in Strep. suis was found in
Denmark during investigations 10 years apart (Aarestrup and
Schwarz, 2006). In selected EU countries in 2002, resistance of
Strep. suis to erythromycinwas 19–65% (Hendriksen et al., 2008). In
France, resistance was reported to be as high as 72–77% towards
spiramycin and tylosin and 69% for lincomycin (AFSSA, 2009). In
the German surveillance data from 2008, 30–45% of isolates were
resistant to erythromycin (BVL, 2008).
Resistance among some zoonotic and indicator bacteria
There are clear differences in resistance of Campylobacter spp.
originating from food animals across the EU (de Jong et al., 2009;
EFSA/ECDC, 2013). C. jejuni from poultry is considered to be the
main source of zoonotic Campylobacter; cattle and pigs are less
important sources. However, macrolide resistance is substantially
more common in C. coli than in C. jejuni (Payot et al., 2006;
Belanger and Shryock, 2007). In the EU around 25% of porcine
C. coli isolates were resistant to erythromycin, ranging from 0% in
Sweden to 63 % in Spain (six countries reporting) (EFSA/ECDC,
2013). Data from The Netherlands showed that C. jejuni isolated
from food animals has no erythromycin resistance but 15% of C. coli
isolates did (MARAN, 2013).
In Denmark, approximately 80% of E. faecium isolated from pigs
in the late 1990s were resistant to tylosin and 50–70% resistant to
virginiamycin (Aarestrup et al., 2000). After the ban on tylosin,
spiramycin and virginiamycin as feed additives within the EU
in 1998, the proportions of macrolide-resistant enterococci
decreased in countries with previously very high ﬁgures (DANMAP,
2012; MARAN, 2007–2008). At the same time, consumption of
tylosin in the Danish pig industry decreased from almost 80 tons to
about 20 tons (DANMAP, 2012). In The Netherlands in 2012, resis-
tance to erythromycin of E. faecalis and E. faecium from cattle
and pigs was 61% and 47%, respectively (MARAN, 2013), although
since 2010, the proportion of resistant isolates of E. faecium has
decreased. In Finland and Sweden, where use of ML antibiotics is
limited compared with most other European countries (EMA/
ESVAC, 2012), erythromycin resistance of enterococci isolated from
cattle and pigs has ranged from 15% to 45% (FINRES-Vet, 2005–
2009; SVARM, 2002–2010).
Clostridium spp. are normal microbiota but some are opportu-
nistic pathogens which can cause enteric diseases in humans and
animals. Only a few reports on the susceptibility of C. perfringens
of porcine isolates are available, but ML resistance is common
(Franklin et al., 2006). C. diﬃcile is a leading cause of nosocomial
diarrhoea in humans and also causes enteric infections in piglets.
Ribotype 078 has recently been increasingly isolated in both
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humans and pigs (Keessen et al., 2013). Isolates were mostly sus-
ceptible to clindamycin, but resistant to erythromycin, with human
isolates being more resistant than porcine ones. The authors
suggested that human and piglet type 078 isolates may have a
common origin.
Discussion
A very high number of products containing ML antimicrobials
are available. The indications and dosages of the old, nationally
authorised macrolide products show a great variation, and their
eﬃcacy data are limited or non-existent. The approved duration of
treatment for some old in-feed ML products is very long, up to 5
weeks, which raises concerns about possible use for growth pro-
moting purposes. The most recently approved macrolides share
once-only dosing regimen and the elimination of the substances is
very slow. This regimen apparently meets the requirements for
convenient treatment protocols of young cattle in the ﬁeld condi-
tions. Whether this is an optimal duration of the treatment (i.e. if
the drug needs to be present in the tissues for 3–4 weeks as is
maintained by these long-acting products) remains open to debate
(Giguère et al., 2011; Menge et al., 2012).
In addition to the target pathogens, the exposure of the whole
microbiome of the animal to the active substance is long, which
could lead to the development of antimicrobial resistance. Even
very low antibiotic concentrations have been shown to select for
resistance (Gullberg et al., 2011). Studies comparing the eﬃcacy of
long- versus short-acting macrolides would be warranted. Another
concern related to one-shot-only macrolide products is related to
animal welfare: according to the summary of product characteris-
tics of the products, pain and reactions at the injection site are
commonly seen and they may last for weeks.
The indications for in-feed ML combination products can be
particularly broad. The justiﬁcation of the combinations over
single components has not been proven, as the products were
approved before speciﬁc requirements for demonstration of eﬃ-
cacy of ﬁxed combination products were implemented (EMEA/
CVMP, 2006a). To decrease the risk for resistance development it
would be necessary to update and harmonise the dosing regimens
of ML antibiotics in the EU, in particular those of the in-feed prod-
ucts used for long periods. Approvals of the combination products
should be renewed and those with no justiﬁcation should be with-
drawn from the market.
The increase of macrolide resistance, in particular for C. coli
from pigs after macrolide use as growth promoter and for treat-
ment, has been documented in several studies (Aarestrup et al.,
1997; Van Looveren et al., 2001). If the use is restricted, resistance
among Campylobacter spp. can decrease markedly, as seen in
Denmark after the ban of tylosin for growth promotion (DANMAP,
2012). The dynamics of antimicrobial resistance in C. coli was
studied on a large pig farm in Finland (Juntunen et al., 2010), where
tylosin treatment was selected for a high rate of resistance towards
erythromycin, which signiﬁcantly decreased when treatment was
discontinued.
ML are important antimicrobials for the treatment of infec-
tions in cattle and pigs, though they are seldom the sole
alternative for treatment. They share some advantageous pharma-
cokinetic characteristics such as good penetration into tissues and
high intracellular concentrations, which makes them an attractive
choice for several indications (Giguère 2013a, 2013b). Macrolides,
like tilmicosin and tulathromycin, are recommended in national
treatment guidelines and textbooks for the treatment of bovine
respiratory disease in cattle, as alternatives to benzylpenicillin,
oxytetracycline, or phenicols (Anonymous, 2003, 2012; Constable
et al., 2008). The majority of respiratory pathogens of cattle have
still remained susceptible to ML antibiotics, despite the decades-
long use of these substances. Macrolides are better choices than
critically important drugs such as ﬂuoroquinolones or extended
spectrum cephalosporins which also have bovine respiratory
disease (BRD) as label indication, but should be used with caution
(Anonymous, 2003; Constable et al., 2008). In the EU, the latter
must have speciﬁc warning sentences in their summary of
product characteristics, which means they should be second
line treatments only (EMEA/CVMP, 2006b; EMA/CVMP/SAGAM,
2009).
ML have limited uses for the treatment of bovine mastitis
caused by Gram-positive pathogens (Deluyker et al., 2005; Consta-
ble et al., 2008). Mastitis-causing streptococci have remained fully
susceptible to benzylpenicillin (SVARM, 2002–2010; MARAN,
2007–2008; Hendriksen et al., 2008). Frequent use of ML for the
treatment of mastitis in some countries may have contributed to
the high prevalence of resistance mastitis-causing streptococci.
Macrolides could be regarded as an alternative for treatment of
mastitis caused by penicillin-resistant Staph. aureus. However, cure
rates of mastitis caused by Staph. aureus with spiramycin or
pirlimycin treatment have been reported to be low (Pyörälä and
Pyörälä, 1998; Middleton et al., 2007). Culling seems to be a better
option due to the poor prognosis and risk of spreading of the
intramammary infections (Barkema et al., 2006).
For the treatment of swine dysentery caused by
B. hyodysenteriae, macrolides have been the drugs-of-choice in
addition to tiamulin and valnemulin (Giguère 2013a, 2013b). Due
to widespread resistance, in many countries macrolides can only
be used after susceptibility testing. Decreased susceptibility to
tiamulin in B. hyodysenteriae isolates has also been reported
(Gresham et al., 1998; Lobova et al., 2004), but it must be
emphasised that no approved breakpoints for susceptibility testing
are available. For diarrhoea caused by B. pilosicoli, pleuromutilins
have been the ﬁrst choice, but resistance to tiamulin has emerged
and percentages of resistance from 5–16% to them have been
reported (Fossi et al., 1999; Pringle et al., 2006b). For porcine pro-
liferative enteropathy caused by L. intracellularis, pleuromutilins or
tetracyclines are the ﬁrst choices, and macrolides are the second
choice (Burch et al., 2008). The therapeutic arsenal for major swine
gastrointestinal infections is already limited, and strict prudent use
principles should be adapted to slow down the development of
antimicrobial resistance of the causing agents. Increases in macro-
lide, lincosamide and pleuromutilin resistance would considerably
worsen the situation.
For swine enzootic pneumonia caused by M. hyopneumoniae as
well as mycoplasmal arthritis, lincomycin and macrolides are
important alternatives to pleuromutilins. Tylosin or lincomycin is
used for neonatal diarrhoea in piglets caused by C. perfringens,
as an alternative to penicillins. Swine pneumonia caused by
A. pleuropneumoniae and P. multocida has remainedmostly suscep-
tible to penicillins, but macrolides are also used. Increasing resis-
tance towards ML would not result in a situation of no treatment
alternatives for pigs, but would seriously restrict alternatives avail-
able for treatment.
Macrolides are considered as critically important and
lincosamides as highly important in human medicine (WHO,
2011). In humans, macrolides are used mostly for non-food-borne
bacterial infections with the exception of Campylobacter and pos-
sibly Salmonella spp. (Gunell et al., 2010). Food-borne pathogens,
but also bacteria infecting humans not linked directly to food of
animal origin may acquire resistance determinants from bacteria
originating from food-producing animals. Prudent use of all anti-
microbials includingML antibiotics approved for food animals is of
utmost importance. Antimicrobials should never be used to com-
pensate for inadequate management of food animals, and all pre-
ventive measures such as consecutive production cycles and
vaccinations should be applied.
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Conclusions
Macrolides and lincosamides (ML) are important antimicrobials
for the treatment of infections in cattle and pigs, although seldom
the sole alternative. The most common indications for ML are the
treatment of major swine gastrointestinal and respiratory infec-
tions and of bovine respiratory disease. The number of old prod-
ucts containing ML in the EU is substantial, and updating and
harmonising the dosing regimens of these products are necessary.
Acquired resistance to ML antimicrobials among food animal
pathogens, including some zoonotic bacteria, has emerged, with
the greatest increase in resistance in Brachyspira. In-feed medica-
tions and long-acting injections resulting in low concentrations of
the active substance for long periods may particularly contribute
to the development of antimicrobial resistance. Macrolides are
considered as critically important and lincosamides as highly
important in human medicine, but these substances are mostly
used for non-food-borne infections. Prudent use of ML antimicro-
bials approved for food animals is of crucial importance to main-
tain the eﬃcacy of these important therapeutic alternatives.
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